

AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

<sup>14</sup>  
Claims 1-15 (canceled)

<sup>14</sup>  
1-15 (new) A liquid polymeric composition for controlled release of eprinomectin consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

(c) at least one lipophilic solvent or a mixture of hydrophilic and lipophilic solvents, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 5:95.

<sup>15</sup>  
2-15 (new) The composition of claim 16 wherein the lipophilic solvent is triacetin.

<sup>15</sup>  
3-15 (new) The composition of claim 16 wherein the hydrophilic solvent is N-methyl pyrrolidone.

<sup>16</sup>  
4-16 (new) The composition of claim 17 wherein the hydrophilic solvent is N-methyl pyrrolidone.

<sup>16</sup>  
5-16 (new) The composition of claim 17 consisting essentially of:

- (a) 1 to 10% of eprinomectin;
- (b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less

and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

6/20  
21.

(c) triacetin.

(new) The composition of claim 19 consisting essentially of:

(a) 1 to 10% of eprinomectin;

(b) 1 to 10% of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the eprinomectin is 1:1 or less and the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35; and

(c) triacetin and N-methyl pyrrolidone, wherein the volume ratio of the triacetin and N-methyl pyrrolidone is from about 80:20 to about 5:95 .

7/21  
22.

(new) The composition of claim 20 wherein (a) consists essentially of about 5% eprinomectin.

8/22  
23.

(new) The composition of claim 21 wherein (a) consists essentially of about 5% eprinomectin.

9/23  
24.

(new) The composition of claim 22 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

10/24  
25.

(new) The composition of claim 23 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is about 75:25.

11/25  
26.

(new) The composition of claim 24 wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

12/26  
27.

(new) The composition of claim 25 wherein (b) is 5% poly(lactide-co-glycolide) copolymer.

13/27  
28.

(new) A method for the controlled release of eprinomectin in a mammal which comprises injecting said mammal with the composition of any one of claims 16-

14/28  
29.

(new) The method of claim 28 wherein the mammal is a bovine.

15/29  
30.

(new) The method of claim 28 wherein the mammal is an ovine.

16/30  
31.

(new) The method of claim 28 wherein the mammal is a canine.—